Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000539291 | SCV000650677 | likely benign | Myofibrillar myopathy 6; Dilated cardiomyopathy 1HH | 2024-11-15 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000539291 | SCV000894524 | uncertain significance | Myofibrillar myopathy 6; Dilated cardiomyopathy 1HH | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004024186 | SCV003697727 | uncertain significance | Cardiovascular phenotype | 2022-01-26 | criteria provided, single submitter | clinical testing | The c.926G>A (p.R309Q) alteration is located in exon 4 (coding exon 4) of the BAG3 gene. This alteration results from a G to A substitution at nucleotide position 926, causing the arginine (R) at amino acid position 309 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Gene |
RCV004760587 | SCV005373358 | uncertain significance | not provided | 2023-05-24 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis supports that this missense variant does not alter protein structure/function |